Previous 10 | Next 10 |
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Retailers cap off the Q1 earnings season in style as Target (TGT), Best Buy (BBY), ...
Stealth BioTherapeutics (NASDAQ: MITO ): Q1 GAAP EPS of -$0.20. More news on: Stealth BioTherapeutics Corp, Earnings news and commentary, Healthcare stocks news, Read more ...
BOSTON , May 15, 2019 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today reported financial result...
BOSTON , May 14, 2019 /PRNewswire/ -- Stealth BioTherapeutics (NASDAQ:MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy ,...
The following slide deck was published by Stealth BioTherapeutics Corp in conjunction with this Read more ...
Results from an open-label Phase 1 clinical trial evaluating Stealth BioTherapeutics' (NASDAQ: MITO ) elamipretide in patients with dry age-related macular degeneration (AMD) showed a treatment effect. The data were presented at ARVO in Vancouver. More news on: Stealth BioTherapeutics...
BOSTON , April 30, 2019 /PRNewswire/ -- Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, recently presented positive results fro...
Gilead Sciences ( GILD ) - The company announced that a phase 3 NASH study for key asset selonsertib failed to meet its primary endpoint. Dubbed STELLAR-3, the trial was investigating the oral inhibitor of ASK1 in patients with bridging fibrosis (F3) due to nonalcoholic steatohepatitis. Th...
Stealth BioTherapeutics ( MITO -0.2% ) announces the full enrollment of 218 subjects in a Phase 3 clinical trial, MMPOWER-3 , evaluating elamipretide in patients with primary mitochondrial myopathy (PMM), a Fast Track and Orphan drug indication in the U.S. More news on: Stealth BioThe...
BOSTON , April 25, 2019 /PRNewswire/ -- Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced completion of...
News, Short Squeeze, Breakout and More Instantly...
Stealth BioTherapeutics Corp. Company Name:
MITO Stock Symbol:
NYSE Market:
Stealth BioTherapeutics Corp Announces Completion of Merger PR Newswire BOSTON , Nov. 16, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO) (the "Company" or "Stealth BioTherapeutics"), a clinical-stage biotechnology company focused on the ...
Stealth BioTherapeutics Announces SBT-272 Data Updates and Orphan Drug Designation for the Treatment of Amyotrophic Lateral Sclerosis (ALS) PR Newswire SBT-272 Phase 1 safety and tolerability data support further clinical development SBT-272 was neuroprotective...
Stealth BioTherapeutics Corp to Hold Extraordinary General Meeting of Shareholders PR Newswire BOSTON , Oct. 7, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO) ("Stealth" or the "Company"), a clinical-stage biotechnology company focused o...